The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Align Technology Inc (NASDAQ:ALGN)

• On Oct. 5, Evercore ISI Group analyst Elizabeth Anderson downgraded Align Technology from Outperform to In-Line and lowered the price target from $220 to $155. The company’s stock fell around 8% over the past month and has a 52-week low of $124.91.
• RSI Value: 29.9
• ALGN Price Action: Shares of Align Technology fell 2.2% to close at $140.65 on Monday.
• Edge Stock Ratings: 17.51 Momentum score with Value at 73.44.

Dianthus Therapeutics Inc (NASDAQ:DNTH)   

• On Oct. 1, Dianthus Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company’s stock fell around 19% over the past month and has a 52-week low of $32.28.
• RSI Value: 29.3
• DNTH Price Action: Shares of Dianthus Therapeutics fell 0.2% to close at $88.04 on Monday.
• Benzinga Pro’s charting tool helped identify the trend in DNTH stock.

Ocular Therapeutix Inc (NASDAQ:OCUL)

• On Sept. 29, Needham analyst Serge Belanger reiterated Ocular Therapeutix with a Buy and maintained a price target of $18. The company’s stock fell around 36% over the past month and has a 52-week low of $6.23.
• RSI Value: 29.2
• OCUL Price Action: Shares of Ocular Therapeutix gained 4.2% to close at $7.25 on Monday.
• Benzinga Pro’s signals feature notified of a potential breakout in OCUL shares.

Curious about other BZ Edge Rankings? Click here to discover how similar stocks measure up.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.